NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $6.35 -0.32 (-4.80%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$6.34 -0.01 (-0.16%) As of 10/30/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Myriad Genetics Stock (NASDAQ:MYGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Myriad Genetics alerts:Sign Up Key Stats Today's Range$6.28▼$6.6650-Day Range$3.05▼$6.6752-Week Range$2.74▼$8.38Volume1.50 million shsAverage Volume3.19 million shsMarket Capitalization$607.38 millionP/E RatioN/ADividend YieldN/APrice Target$4.77Consensus RatingHold Company Overview Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications. Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer. Myriad also offers GeneSight, a pharmacogenomic test intended to help inform medication selection for certain mental health conditions, as well as other diagnostic services designed to support personalized treatment and disease management. Founded in 1991, Myriad Genetics is headquartered in Salt Lake City, Utah. The company serves healthcare providers, patients, health systems, laboratories and pharmaceutical partners, primarily in the United States, with selected products and services available internationally. Nicole Lambert serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Myriad Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreMYGN MarketRank™: 1.26895920502 of 5 starsMyriad Genetics scored higher than 25% of companies evaluated by MarketBeat, and ranked 814th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 6 hold ratings, and 1 sell rating.Downside RiskMyriad Genetics has a consensus price target of $4.77, representing about 24.9% downside from its current price of $6.35.Amount of Analyst CoverageMyriad Genetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Myriad Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.99) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.88% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 5.32.Change versus previous monthShort interest in Myriad Genetics has recently increased by 8.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.89 News SentimentMyriad Genetics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search Interest5 people have searched for MYGN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders1.90% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Stock News HeadlinesMolecular Partners (NASDAQ:MOLN) vs. Myriad Genetics (NASDAQ:MYGN) Head-To-Head SurveyOctober 28, 2026 | americanbankingnews.comMyriad Genetics consensus price target increased by 33.29% to $4.58October 23, 2026 | msn.comCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it. | Digest Publishing (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Elevance Health (ELV) and Myriad Genetics (MYGN)October 23, 2026 | theglobeandmail.comMyriad Genetics Reports New MRD Detection Data In Colorectal And Pancreatic CancersOctober 22, 2026 | rttnews.comMyriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst RevisionsOctober 22, 2026 | finance.yahoo.comMyriad Genetics: Prenatal Sale Provides A Lifeline In A Tough SpotOctober 22, 2026 | seekingalpha.comMyriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic CancersOctober 22, 2026 | globenewswire.comSee More Headlines MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $6.15 on January 1st, 2026. Since then, MYGN shares have increased by 3.3% and is now trading at $6.35. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Thursday, July, 30th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.19. The business's revenue for the quarter was down 10.5% on a year-over-year basis. Read the conference call transcript. Does Myriad Genetics have any subsidiaries? Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more. Who are Myriad Genetics' major shareholders? Top institutional shareholders of Myriad Genetics include Assenagon Asset Management S.A. (0.98%), State of Wyoming (0.12%), Vise Technologies Inc. (0.03%) and Williams & Novak Wealth Management LLC (0.02%). Insiders that own company stock include Paul J Diaz, Samraat S Raha, Richard Bryan Riggsbee, S Louise Phanstiel, Rashmi Kumar, Heinrich Dreismann, Paul Bisaro, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), STMicroelectronics (STM), Gilead Sciences (GILD), Bristol Myers Squibb (BMY) and Tesla (TSLA). Company Calendar Last Earnings7/30/2026Today11/01/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MYGN's financial health is in the Green zone, according to TradeSmith. MYGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Price Target for Myriad Genetics$4.77 High Price Target$8.00 Low Price Target$3.00 Potential Upside/Downside-24.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$365.90 million Net Margins-13.96% Pretax Margin-13.86% Return on Equity-16.09% Return on Assets-8.10% Debt Debt-to-Equity Ratio0.40 Current Ratio2.21 Quick Ratio1.98 Sales & Book Value Annual Sales$824.50 million Price / Sales0.74 Cash Flow$3.76 per share Price / Cash Flow1.69 Book Value$3.95 per share Price / Book1.61Miscellaneous Outstanding Shares95,650,000Free Float93,833,000Market Cap$607.38 million OptionableOptionable Beta1.64 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MYGN) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
